We are live on
!
Find out more
BCM
Burrage Capital Management Portfolio holdings
AUM
$99.7M
1-Year Est. Return
66.05%
This Fund
S&P 500
This Quarter
Est. Return
+51.27%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$143M
AUM Growth
+$41.3M
(+41%)
Cap. Flow
+$180K
Cap. Flow
% of AUM
0.13%
Top 10 Holdings %
Top 10 Hldgs %
59.86%
Holding
34
New
3
Increased
4
Reduced
11
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADC Therapeutics
ADCT
|
+$5.12M |
| 2 |
Fulcrum Therapeutics
FULC
|
+$4.59M |
| 3 |
AIMT
Aimmune Therapeutics
AIMT
|
+$3.74M |
| 4 |
Insmed
INSM
|
+$2.37M |
| 5 |
MRUS
Merus
MRUS
|
+$2.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CytomX Therapeutics
CTMX
|
+$3.46M |
| 2 |
TVRD
Tvardi Therapeutics
TVRD
|
+$3.29M |
| 3 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$2.78M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$2.11M |
| 5 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$1.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPZM
1
DELISTED
Epizyme, Inc
EPZM
| $14.3M | 10.02% |
891,277
-2,421
| -0.3% | -$42.3K |
|
|
LITS
2
Lite Strategy Inc
LITS
$33.6M
| $12.4M | 8.67% |
150,058
-845
| -0.6% | -$51.2K |
|
3
PTC Therapeutics
PTCT
$6.52B
| $9.1M | 6.37% |
179,386
-1,851
| -1% | -$91K |
|
|
GTHX
4
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $9.07M | 6.35% |
373,876
-4,269
| -1% | -$70.6K |
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.53M | 5.27% |
1,476,871
-44,511
| -3% | -$185K |
|
6
OrthoPediatrics
KIDS
$493M
| $7.42M | 5.19% |
169,468
-1,645
| -1% | -$74K |
|
7
AnaptysBio
ANAB
$1.72B
| $7.33M | 5.13% |
328,114
-3,805
| -1% | -$69.6K |
|
|
8
ADC Therapeutics
ADCT
$172M
| $6.32M | 4.42% |
+134,912
| New | +$5.12M |
|
9
Cytokinetics
CYTK
$10.9B
| $6.16M | 4.31% |
261,491
-56,782
| -18% | -$1.06M |
|
10
NeoGenomics
NEO
$1.9B
| $5.89M | 4.12% |
190,205
-2,072
| -1% | -$57.4K |
|
|
AIMT
11
DELISTED
Aimmune Therapeutics
AIMT
| $5.56M | 3.89% |
332,546
+220,000
| +195% | +$3.74M |
|
|
12
Fulcrum Therapeutics
FULC
$243M
| $5.33M | 3.73% |
+291,645
| New | +$4.59M |
|
|
YMAB
13
DELISTED
Y-mAbs Therapeutics
YMAB
| $5.32M | 3.72% |
123,025
-48,763
| -28% | -$1.84M |
|
|
TPTX
14
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $4.99M | 3.49% |
77,172
| – | – |
|
15
Korro Bio
KRRO
$177M
| $4.74M | 3.32% |
4,078
+600
| +17% | +$542K |
|
|
16
Insmed
INSM
$23.5B
| $4.55M | 3.19% |
165,400
+100,000
| +153% | +$2.37M |
|
17
Regenxbio
RGNX
$511M
| $4.24M | 2.96% |
115,000
| – | – |
|
18
Aurinia Pharmaceuticals
AUPH
$2.05B
| $4.17M | 2.92% |
256,438
+60,000
| +31% | +$961K |
|
19
Crinetics Pharmaceuticals
CRNX
$8.88B
| $4.14M | 2.9% |
236,394
-45,878
| -16% | -$782K |
|
|
TECX
20
Tectonic Therapeutic
TECX
$615M
| $3.94M | 2.76% |
18,825
| – | – |
|
|
ADVM
21
DELISTED
Adverum Biotechnologies
ADVM
| $3.26M | 2.28% |
15,601
| – | – |
|
|
APLS
22
DELISTED
Apellis Pharmaceuticals
APLS
| $2.43M | 1.7% |
74,452
| – | – |
|
|
MRUS
23
DELISTED
Merus
MRUS
| $2.25M | 1.58% |
+140,176
| New | +$2.03M |
|
|
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
| $1.89M | 1.32% |
70,000
| – | – |
|
|
KDNY
25
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $314K | 0.22% |
27,180
| – | – |
|
Similar funds
WCM
CCM
RGM
TCM
RC
AC
QVT
WFWM
Burrage Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Burrage Capital Management held 34 positions worth $143M, up 41% from $102M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Burrage Capital Management's Q2 2020 filing shows 3 new, 4 increased, 11 reduced and 8 closed positions. Its largest new stake was ADC Therapeutics: 134,912 shares worth $6.32M. The largest sale was CytomX Therapeutics, an estimated $3.46M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.
- Burrage Capital Management's largest Q2 2020 buy was ADC Therapeutics: 134,912 shares worth $6.32M.
- Burrage Capital Management added most to Aimmune Therapeutics in Q2 2020, an estimated $3.74M increase.
- Burrage Capital Management's biggest Q2 2020 reduction was Y-mAbs Therapeutics, cutting an estimated $1.84M.
- Burrage Capital Management fully exited CytomX Therapeutics in Q2 2020, selling an estimated $3.46M.
- Burrage Capital Management's ten largest holdings make up 60% of its $143M portfolio in Q2 2020.
- Burrage Capital Management opened 3 new positions and closed 8 in Q2 2020.
- Burrage Capital Management's portfolio value rose 41% quarter-over-quarter to $143M.
Based on Burrage Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.